Understanding patient barriers and facilitators to uptake of lung screening using low dose computed tomography: a mixed methods scoping review of the current literature

Autor: Debbie Cavers, Mia Nelson, Jasmin Rostron, Kathryn A. Robb, Lynsey R. Brown, Christine Campbell, Ahsan R. Akram, Graeme Dickie, Melanie Mackean, Edwin J. R. van Beek, Frank Sullivan, Robert J. Steele, Aileen R. Neilson, David Weller

Publikováno v: Respiratory Research, Vol 23, Iss 1, Pp 1-18 (2022)

Abstract Background Targeted lung cancer screening is effective in reducing mortality by upwards of twenty percent. However, screening is not universally available and uptake is variable and socially patterned. Understanding screening behaviour is in

Externí odkaz: https://doaj.org/article/28e3858aa679463080c1aedfe7cd4aa2

Experiences of cervical screening participation and non‐participation in women from minority ethnic populations in Scotland

Autor: Mia Nelson, Andrea Patton, Katie Robb, David Weller, Aziz Sheikh, Kalpana Ragupathy, David Morrison, Christine Campbell

Publikováno v: Health Expectations, Vol 24, Iss 4, Pp 1459-1472 (2021)

Abstract Background The introduction of screening in the UK and other high‐income countries led to a significant decrease in the incidence of cervical cancer and increase in survival rates. Minority ethnic groups are often underrepresented in scree

Externí odkaz: https://doaj.org/article/55f43796c320479691b5b5b99d7d547f

What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health‐care professionals? A systematic review

Autor: Claire Tochel, Michael Smith, Helen Baldwin, Anders Gustavsson, Amanda Ly, Christin Bexelius, Mia Nelson, Christophe Bintener, Enrico Fantoni, Josep Garre‐Olmo, Olin Janssen, Christoph Jindra, Isabella F. Jørgensen, Alex McKeown, Buket Öztürk, Anna Ponjoan, Michele H. Potashman, Catherine Reed, Emilse Roncancio‐Diaz, Stephanie Vos, Cathie Sudlow, the ROADMAP consortium

Publikováno v: Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 11, Iss 1, Pp 231-247 (2019)

Abstract Introduction Clinical trials involving patients with Alzheimer's disease (AD) continue to try to identify disease‐modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outc

Externí odkaz: https://doaj.org/article/57e677c42d614929bedcb9d26f020449

Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes

Autor: Annette Bauer, Catherine Sudlow, Anders Gustavsson, Amanda Ly, Claire Tochel, Raphael Wittenberg, Christin Bexelius, Mia Nelson, Martin Knapp

Publikováno v: Bauer, A, Wittenberg, R, Ly, A, Gustavssond, A, Bexelius, C, Tochel, C, Knapp, M, Nelson, M & Sudlow, C L M 2020, ' Valuing Alzheimer's Disease drugs : A health technology assessment perspective on outcomes ', International journal of technology assessment in health care, pp. 1-7 . https://doi.org/10.1017/S0266462320000574

ObjectivesDue to the nature of Alzheimer's disease (AD), health technology assessment (HTA) agencies might face considerable challenges in choosing appropriate outcomes and outcome measures for drugs that treat the condition. This study sought to und

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fdbc859ea64c708680914d5c31e72a6
https://doi.org/10.1017/s0266462320000574

What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals?

Autor: Christophe Bintener, Michael Sharwood Smith, Michele Potashman, Amanda Ly, Alex McKeown, Christoph Jindra, Anders Gustavsson, Emilse Roncancio-Diaz, Cathie Sudlow, Olin Janssen, Anna Ponjoan, Claire Tochel, Stephanie J.B. Vos, Isabella Friis Jørgensen, Buket Öztürk, Catherine Reed, Josep Garre-Olmo, Mia Nelson, Christin Bexelius, Helen Baldwin, Enrico R. Fantoni

Publikováno v: Tochel, C, Smith, M, Baldwin, H, Gustavsson, A, Ly, A, Bexelius, C, Nelson, M, Bintener, C, Fantoni, E, Garre-Olmo, J, Janssen, O, Jindra, C, Jørgensen, I F, McKeown, A, Öztürk, B, Ponjoan, A, Potashman, M H, Reed, C, Roncancio-Diaz, E, Vos, S & Sudlow, C 2019, ' What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review ', Alzheimer's & Dementia, vol. 11, pp. 231-247 . https://doi.org/10.1016/j.dadm.2018.12.003
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Alzheimers & Dementia: Diagnosis, Assessment & Disease Monitoring
Tochel, C, Smith, M, Baldwin, H, Gustavsson, A, Ly, A, Bexelius, C, Nelson, M, Bintener, C, Fantoni, E, Garre-Olmo, J, Janssen, O, Jindra, C, Jorgensen, I, McKeown, A, Ozturk, B, Ponjoan, A, Potashman, M, Reed, C, Roncancio-Diaz, E, Vos, S & Sudlow, C 2019, ' What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review ', Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring . https://doi.org/10.1016/j.dadm.2018.12.003
Tochel, C, Smith, M, Baldwin, H, Gustavsson, A, Ly, A, Bexelius, C, Nelson, M, Bintener, C, Fantoni, E, Garre-Olmo, J, Janssen, O, Jindra, C, Jørgensen, I F, McKeown, A, Öztürk, B, Ponjoan, A, Potashman, M H, Reed, C, Roncancio-Diaz, E, Vos, S, Sudlow, C & ROADMAP consortium 2019, ' What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review ', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 11, pp. 231-247 . https://doi.org/10.1016/j.dadm.2018.12.003
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 11(1), 231-247. Elsevier BV
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 11, Iss 1, Pp 231-247 (2019)

Introduction: Clinical trials involving patients with Alzheimer’s disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outcomes of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b9fc902e29a50872ed92ca7654b159
https://cris.maastrichtuniversity.nl/en/publications/0f468330-2ae5-4972-b0a4-e3b057ce4213